Page Title
Drug Development Pipeline
Inhaled Mannitol (Bronchitol®)
Status
To PatientsTherapeutic Approach
Mucociliary Clearance
Bronchitol® is an inhaled dry powder form of mannitol, a naturally occurring osmotic agent, which works by drawing water into the airways. This helps to moisten and thin the sticky mucus found in the lungs of people with CF, making it easier to cough it out.
Status
Inhaled mannitol is approved for people with CF 18 years of age and older.
A phase 3 study of inhaled mannitol in adults with CF was completed in 2017. This study found that participants who received mannitol had greater improvements in lung function than those who received placebo.
Sponsor
The program is sponsored by Chiesi USA and Pharmaxis. Trials were conducted within the Therapeutics Development Network.
Recent Inhaled Mannitol (Bronchitol®) Studies
-
Completed with Results
Phase 3 study of inhaled mannitol in adults with cystic fibrosis (Pharmaxis DPM-CF-303)
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More